基于全转录组学探讨仙连解毒方治疗Ⅲ期结直肠癌患者的疗效机制 [中文引用][英文引用]

【摘要】目的 通过转录组测序技术探讨仙连解毒方治疗Ⅲ期结直肠癌患者的潜在疗效机制。方法 本研究针对Ⅲ期结直肠癌患者，随机选取仙连解毒方给药组和未接受仙连解毒方给药（对照组）的肿瘤组织样本各4例，进行全转录组测序，鉴定差异表达基因、富集功能通路及构建miRNA-mRNA调控网络。结果 通过两组样本比较，服用仙连解毒方的结直肠癌患者样本中存在多个差异表达的miRNA、mRNA，包括hsa-miR-105-5p、hsa-miR-129-1-3p和hsa-miR-135a-5p等，及ANKRD31、ESPNL和DACT2等。功能富集分析显示仙连解毒方治疗后，膜转运功能、类固醇激素应答、IL-4及IL-13等肿瘤相关通路显著富集。结论：仙连解毒方可能通过调控miRNA、mRNA的表达水平，影响相关通路，从而干预Ⅲ期结直肠癌患者的肿瘤进展。

 [Abstract]  Objective  To explore the potential mechanism of Xianlian Jiedu decoction (XLJDD) in the treatment of stage Ⅲ colorectal cancer patients via transcriptome sequencing technology. Methods  This study focused on patients with stage Ⅲ colorectal cancer. Four tumor tissue samples were randomly selected from the XLJDD group and four from the control group who did not receive XLJDD. Full transcriptome sequencing was performed to identify differentially expressed genes, enrich functional pathway, and construct a miRNA-mRNA regulatory network. Results  By comparing samples of the two groups, it was found that there were multiple differentially expressed miRNA and mRNA in the samples of colorectal cancer patients taking XLJDD, including hsa-miR-105-5p, hsa-miR-129-1-3p and hsa-miR-135a-5p, as well as ANKRD31, ESPNL and DACT2. Functional enrichment analysis showed that membrane transport function, steroid hormone response, IL-4, IL-13 and other tumor-related pathways were significantly enriched after XLJDD treatment. Conclusion  XLJDD may interfere with the tumor progression of stage Ⅲ colorectal cancer patients by regulating the expression levels of miRNA and mRNA and affecting related pathways.